Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
NCT04200651
Terminated
In this study, the investigators are comparing dexamethasone ophthalmic insert (DEXTENZA®) to the current standard of care, prednisolone acetate 1% eye drops, in a glaucoma population receiving both cataract and minimally-invasive glaucoma surgery (MIGS). DEXTENZA® and prednisolone acetate 1% drops are both steroids used to control inflammation after eye surgery. DEXTENZA®'s method of delivery differs by offering a sustained release of steroid that does not necessitate postoperative anti-inflamm... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/07/2024
Locations: The New York Eye Surgery Center, Bronx, New York
Conditions: Glaucoma, Cataract
Register for Updates
A Rollover Study of CC-122
NCT05688475
Active Not Recruiting
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Local Institution - 100, New York, New York +6 locations
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT03506360
Completed
This phase II trial studies how well pembrolizumab works when given together with ixazomib citrate and dexamethasone in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
NCT03247413
Terminated
Chronic neck and back pain has become one of the leading causes of disability and loss of productivity. For many patients with facet or sacroiliac joint mediated pain who have responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the joints can provide long term relief. Radiofrequency ablation (RFA) is a relatively safe procedure with minimal risk of adverse events. However, with any procedure involving damage to the peripheral nervous system, there is risk of p... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/01/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Neuritis, Radiofrequency Ablation
Register for Updates
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
NCT02697344
Completed
This phase I trial studies the side effects and best dose of R-(-)-gossypol acetic acid when given together with lenalidomide and dexamethasone and to see how well it works in treating patients with multiple myeloma, also known as plasma cell myeloma, that has come back after a period of improvement or has gotten worse after treatment. R-(-)-gossypol acetic acid may stop the growth of cancer cells by recognizing certain proteins and stimulating programmed cell death. Lenalidomide may stimulate o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
NCT02385110
Completed
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH. The safety of the drug combinations will also be studied. This is an investigational study. Alemtuzumab, etoposide, tocilizumab, and dexamethasone are not FDA approved for the treatment of HLH. Etoposide is FDA approved and commercially available for the treatment of testicular cancer and lung cancer. Alemtuzumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
NCT00520767
Completed
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/20/2023
Locations: Rocky Mountain Cancer Centers/Rocky Mountain Blood & Marrow Transplant Program, Denver, Colorado +6 locations
Conditions: Primary Systemic Amyloidosis, Light Chain Deposition Disease
Register for Updates
Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery
NCT05996133
Recruiting
The goal of this randomized, double-blinded, clinical trial is to assess the benefit of administering a Multifidus Cervicis Plane (MCP) block compared to a sham block as a method of postoperative pain control in patients undergoing posterior cervical spine fusion surgery. The main question it aims to answer is if the MCP block group will have reduced maximum pain scores during the first 24 postoperative hours compared to the sham block group. Participants will receive preoperative bilateral MCP... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
12/13/2023
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cervical Spine Fusion
Register for Updates
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
NCT04126278
Terminated
The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/13/2023
Locations: NYU Langone Health, New York, New York
Conditions: Calcific Tendinitis
Register for Updates
Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)
NCT04738318
Terminated
The primary purpose of this study is to determine if perioperative glucocorticoid administration (IV intra-operative followed by a post-operative oral taper course) improves post-operative range of motion in a patient population that has sustained an intra-articular elbow fracture(s) (radial head, proximal ulna, distal humerus, or combined) that required operative fixation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Elbow Fracture
Register for Updates
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299
Active Not Recruiting
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Moffitt Cancer Center, Tampa, Florida +9 locations
Conditions: Smoldering Multiple Myeloma
Register for Updates
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT02843074
Completed
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +5 locations
Conditions: Multiple Myeloma
Register for Updates